Conclusion
hyperuricemia, gout
HYPERURICEMIA, GOUT
In summary, multiple oral doses of 30–120 mg HP501 were well tolerated in patients with hyperuricemia with or without gout. Pharmacokinetic analysis showed that HP501 exposure increased with an increase in the administration dose from 30 to 120 mg. However, pharmacodynamic analysis revealed that the serum UA decline was saturated at the 90 mg dose level. Thus, 90 mg HP501 is recommended for subsequent clinical studies of this highly selective URAT1 inhibitor.